The Effects of Human Papillomavirus Status and Treatment on the Positive Predictive Value of Post-radiotherapy 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Advanced Head and Neck Squamous Cell Carcinoma

Zhou, S.; Chan, C.; Lau, Y.C.; Rulach, R.; Dyab, H.; Hendry, F.; Wilson, C.; Schipani, S.; Lamb, C.; Grose, D.; James, A.; Maxfield, C.; Dempsey, M.-F.; Paterson, C.

doi:10.1016/j.clon.2023.09.006

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDG PET‐CT surveillance 12‐weeks post‐treatment, however, has demonstrated to have a high negative predictive value in this population with good survival outcomes of complete responders. In contrast, the positive predictive value of 12‐week PET‐CT has been shown to be significantly lower for HPV‐positive (22.5%) compared with HPV‐negative (52.7%) HNSCC, which highlights the need of additional biomarkers for better patient stratification 15‐25 . Patients with HPV‐positive OPSCC tend to be younger and because of the better treatment outcomes, are more likely to suffer from treatment‐associated toxicities for decades to come 26 .…”

Section: Introductionmentioning

confidence: 99%

The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

Flach,

Maniam,

Hey

et al. 2024

Clinical Otolaryngology

View full text Add to dashboard Cite

ObjectivesAbout 17% of patients with human papillomavirus (HPV)‐positive head and neck squamous cell carcinoma (HNSCC), which is mainly comprised of oropharyngeal SCC (OPSCC), will experience disease recurrence, which is often considered incurable when manifested at a metastatic and/or recurrent stage. We conducted a critical qualitative systematic review.Our objectives were to provide an overview of the molecular landscape of recurrent/metastatic HPV‐positive HNSCC as well as novel molecular biomarkers.DesignA literature review was conducted to identify studies reporting on the molecular characteristics of recurrent/metastatic HPV‐positive HNSCC, novel molecular biomarkers and treatment options. The reviews of abstracts, full articles, and revision of the included studies, followed by data extraction and quality assessment were performed by three independent assessors. All primary literature, such as retrospective, prospective, and clinical trials as well as basic research studies were considered, and the final search was conducted at the end of February 2023. The level of evidence was rated using the guidelines published by the Oxford Centre for Evidence‐based Medicine and quality was assessed using the Newcastle‐Ottawa Scale criteria.Results and ConclusionsThe literature search resulted in the identification of 1991 articles. A total of 181 full articles were screened, and 66 articles were included in this analysis. Several studies reported that recurrent/metastatic HPV‐positive HNSCC had higher rates of TP53 mutation and were genomically similar to HPV‐negative HNSCC. The detection of circulating tumour tissue‐modified HPV DNA (ctHPVDNA) as a specific biomarker has shown promising results for monitoring treatment response and recurrence in the subset of HPV‐positive HNSCC. In addition, evidence for targeted therapy in recurrent/metastatic HPV‐positive HNSCC has emerged, including agents that inhibit overexpressed EGFR. Studies of combination immunotherapy are also underway.Our review outlines the latest evidence on the distinct molecular profiles of recurrent/metastatic HPV‐positive HNSCC as well as the clinical potential of ctHPVDNA testing in routine practice. More controlled and longitudinal studies are needed to identify additional molecular targets and to assess the performance and benefits of novel molecular biomarkers in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

Flach,

Maniam,

Hey

et al. 2024

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

Postradiotherapy Response Assessment Using 18F-FDG PET/CT in Salivary Gland Carcinoma—A Multicenter Study

Chen,

Cheng,

Lin

et al. 2024

Clin Nucl Med

View full text Add to dashboard Cite

Purpose This multicenter study investigates the efficacy of 18F-FDG PET/CT in postradiotherapy (post-RT) response evaluation in salivary gland carcinoma (SGC). Methods We retrospectively reviewed 115 SGC patients who underwent definitive or adjuvant RT followed by 18F-FDG PET/CT between 2004 and 2021. Most tumors were parotid gland malignancies (50%). The most common histological subtypes were adenoid cystic (29%) and mucoepidermoid carcinomas (18%). Results The median follow-up was 65 months. Post-RT anatomic images (CT/MRI) revealed complete response (CR) in 51 patients (44%). Among 53 patients with partial response or stable disease, only 17 (32%) patients experienced locoregional recurrence, with a 5-year locoregional control rate of 69%. Post-RT 18F-FDG PET/CT documented metabolic CR in 81 patients (70%). Metabolic complete responders had significantly higher 5-year locoregional control (90% vs 43%), distant metastasis–free survival (80% vs 48%), progression-free survival (76% vs 24%), and overall survival rates (89% vs 42%) compared with non–complete responders (all P < 0.001), as confirmed in both univariate and multivariate analyses. It identified additional viable tumors in 18 cases (16%) and facilitated salvage local therapies in 7 patients (6%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of post-RT 18F-FDG PET/CT were 63%, 91%, 70%, 88%, and 84%, respectively, in predicting locoregional recurrence. 18F-FDG PET/CT showed significantly higher sensitivity (88% vs 36%, P = 0.011) in tumors with pre-RT SUVmax ≥7.39 compared with those with SUVmax <7.39. Conclusions Post-RT 18F-FDG PET/CT demonstrates high negative predictive value and specificity, with metabolic CR predicting excellent outcomes. Additionally, it exhibits higher sensitivity for high-SUVmax SGC, facilitating early detection of viable tumors.

show abstract

The Effects of Human Papillomavirus Status and Treatment on the Positive Predictive Value of Post-radiotherapy 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Advanced Head and Neck Squamous Cell Carcinoma

Cited by 2 publications

References 35 publications

The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature

Postradiotherapy Response Assessment Using 18F-FDG PET/CT in Salivary Gland Carcinoma—A Multicenter Study

Contact Info

Product

Resources

About